5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections

Clinical Overview and Diagnostic Stratification of Respiratory Infections

Respiratory tract infections represent the most frequent indication for antimicrobial prescribing in both ambulatory and acute inpatient settings. Optimizing pharmacotherapy requires precise anatomical localization, distinguishing non-bacterial viral syndromes from invasive bacterial pathogens, establishing disease severity, evaluating multidrug-resistant (MDR) pathogen risk, and selecting antimicrobial regimens with optimal epithelial lining fluid (ELF) and alveolar penetration.

---

Community-Acquired Pneumonia (CAP)

Community-acquired pneumonia (CAP) is an acute infection of the pulmonary parenchyma acquired outside of a hospital or healthcare facility. Despite advances in immunization, CAP remains a leading infectious cause of hospitalization, critical illness, and mortality worldwide.

Etiology and Microbiology

The etiologic landscape of CAP spans classic bacterial pathogens, atypical intracellular organisms, and respiratory viruses:

• Typical Bacterial Pathogens: Streptococcus pneumoniae remains the predominant bacterial pathogen across all demographic cohorts, followed by Haemophilus influenzae (frequently unencapsulated non-typeable strains in COPD and tobacco smokers) and Moraxella catarrhalis.
• Atypical Pathogens: Mycoplasma pneumoniae (epidemic in school-aged children and young adults), Chlamydia pneumoniae, and Legionella pneumophila (facultative intracellular bacillus transmitted via aerosolized environmental water sources).
• Viral Etiologies: Influenza A and B, respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus, and parainfluenza. Primary viral pneumonia frequently predisposes patients to secondary bacterial superinfections, classically S. pneumoniae or Staphylococcus aureus (including CA-MRSA harboring Panton-Valentine leukocidin).

                                 Suspected Community-Acquired Pneumonia (CAP)
                                                      │
                          ┌───────────────────────────┴───────────────────────────┐
                          ▼                                                       ▼
                  Outpatient Setting                                      Inpatient Setting
                          │                                                       │
              ┌───────────┴───────────┐                               ┌───────────┴───────────┐
              ▼                       ▼                               ▼                       ▼
      No Comorbidities        With Comorbidities                 Non-Severe CAP          Severe CAP (ICU)
      • Amoxicillin 1g TID    • Beta-Lactam + Macrolide/         • Beta-Lactam +         • Beta-Lactam +
      • Doxycycline 100mg BID   Doxycycline                        Macrolide, OR           Macrolide, OR
      • Macrolide (if local   • Respiratory FQ                   • Respiratory FQ        • Beta-Lactam +
        resistance < 25%)       Monotherapy                        Monotherapy             Respiratory FQ

Outpatient Empiric Therapy (2019 ATS/IDSA Guidelines)

The 2019 American Thoracic Society / Infectious Diseases Society of America (ATS/IDSA) guideline recommendations stratify outpatient empiric selection fundamentally by patient underlying comorbidities:

1. Outpatient Adults WITHOUT Comorbidities or Risk Factors for Resistant Pathogens:

   • Amoxicillin: 1 g orally three times daily (Strong recommendation, moderate-quality evidence). High-dose amoxicillin provides reliable pharmacodynamic exposure ($T > \text{MIC}$) to overcome low-to-intermediate penicillin resistance mediated by mosaic penicillin-binding protein (PBP2x, PBP2b) alterations in S. pneumoniae.
   • Doxycycline: 100 mg orally twice daily (Conditional recommendation, low-quality evidence). Provides broad coverage against S. pneumoniae and atypical pathogens (M. pneumoniae, C. pneumoniae).
   • Macrolide Monotherapy: Azithromycin (500 mg day 1, then 250 mg daily) or clarithromycin (500 mg BID or 1000 mg extended-release daily). Recommended ONLY in geographic regions where documented pneumococcal macrolide resistance is < 25%. In the United States and most global centers, high-level macrolide resistance via ribosomal methylation (ermB) or macrolide efflux (mefA) exceeds 30% to 40%, making macrolide monotherapy generally unsuitable.

2. Outpatient Adults WITH Comorbidities:

   • Defined as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia.
   • Combination Therapy (Beta-lactam PLUS Macrolide or Doxycycline):
     • Beta-lactam options: Amoxicillin-clavulanate (875/125 mg PO BID, 1000/62.5 mg PO BID, or 2000/125 mg PO BID ER) OR cephalosporins (cefpodoxime 200 mg PO BID or cefuroxime axetil 500 mg PO BID).
     • Plus: Azithromycin 500 mg day 1 then 250 mg daily, clarithromycin 500 mg BID, or doxycycline 100 mg PO BID.
   • Respiratory Fluoroquinolone Monotherapy:
     • Levofloxacin 750 mg orally once daily OR Moxifloxacin 400 mg orally once daily.

Inpatient Empiric Therapy: Non-Severe vs. Severe ICU CAP

Inpatient classification requires rapid severity assessment utilizing validated clinical indices (CURB-65 or Pneumonia Severity Index [PSI/PORT]) and ATS/IDSA severity criteria:

• Severe CAP Criteria: Defined by the presence of at least one major criterion (septic shock requiring vasopressors, or respiratory failure requiring invasive mechanical ventilation) OR at least three minor criteria (respiratory rate $\ge 30$ breaths/min, $\text{PaO}_2/\text{FiO}_2$ ratio $\le 250$, multilobar infiltrates, confusion/disorientation, uremia [BUN $\ge 20$ mg/dL], leukopenia [WBC $< 4,000$ cells/$\mu$L], thrombocytopenia [platelets $< 100,000$ cells/$\mu$L], hypothermia [core temp $< 36^\circ\text{C}$], or hypotension requiring aggressive fluid resuscitation).

Empiric MRSA and Pseudomonas aeruginosa Risk Factors and Nasal PCR De-escalation

The 2019 ATS/IDSA guidelines officially abandoned the prior "Healthcare-Associated Pneumonia" (HCAP) category because it possessed low specificity and led to widespread, unnecessary utilization of broad-spectrum antipseudomonal and anti-MRSA antimicrobials.

Empiric coverage for MRSA or P. aeruginosa is now restricted to patients with validated individual risk factors:

1. Prior respiratory isolation of MRSA or P. aeruginosa within the past 12 months.
2. Recent hospitalization AND receipt of parenteral (IV) antibiotics within the prior 90 days.

When risk factors are present:

• Empiric MRSA Agents: Vancomycin (target AUC/MIC ratio 400–600 mg$\cdot$h/L via Bayesian modeling) OR Linezolid 600 mg IV/PO q12h. Note: Daptomycin is strictly contraindicated in pneumonia because pulmonary surfactant binds and sequesters daptomycin, irreversibly inactivating its bactericidal lipopeptide mechanism!
• Empiric Antipseudomonal Agents: Piperacillin-tazobactam (4.5 g IV q6h as 3-hour or 4-hour extended infusion), Cefepime (2 g IV q8h), Ceftazidime (2 g IV q8h), Meropenem (1 g IV q8h), or Aztreonam (2 g IV q8h).

Duration of Therapy and Clinical Stability Criteria

The ATS/IDSA guidelines recommend a minimum duration of 5 days for uncomplicated community-acquired pneumonia. Antibiotics can be safely discontinued at day 5 provided the patient achieves clinical stability, defined as:

• Afebrile for $\ge 48$ hours without antipyretics.
• Heart rate $< 100$ beats/min.
• Respiratory rate $< 24$ breaths/min.
• Systolic blood pressure $\ge 90$ mmHg.
• Arterial oxygen saturation $\ge 90\%$ or $\text{PaO}_2 \ge 60$ mmHg on ambient room air (or baseline oxygen requirement).
• Maintenance of oral intake and baseline cognitive mental status.

Routine continuation to 7–10 days provides no incremental clinical benefit and increases selective pressure for resistant microflora.

---

Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP)

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent the second most common nosocomial infection and the leading cause of infectious mortality in intensive care units.

Definitions and Pathophysiology

• Hospital-Acquired Pneumonia (HAP): Pneumonia occurring $\ge 48$ hours after hospital admission that was not incubating at the time of admission.
• Ventilator-Associated Pneumonia (VAP): Pneumonia developing $> 48$ hours after endotracheal intubation and mechanical ventilation.
• Microbiology: Characterized by multidrug-resistant pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, and methicillin-resistant S. aureus (MRSA).

Empiric Regimen Selection (2016 IDSA/ATS Guidelines)

All empiric regimens for HAP/VAP must include activity against Staphylococcus aureus and Pseudomonas aeruginosa.

                                        HAP / VAP Empiric Decision Tree
                                                       │
                          ┌────────────────────────────┴────────────────────────────┐
                          ▼                                                         ▼
                   Anti-MRSA Agent                                        Antipseudomonal Agents
                          │                                                         │
              ┌───────────┴───────────┐                         ┌───────────────────┴───────────────────┐
              ▼                       ▼                         ▼                                       ▼
      MRSA Risk Factors:       No MRSA Risk:            Double Antipseudomonal:                 Single Agent:
      • Prior IV abx in 90d    • Cefazolin, Oxacillin,   • Prior IV abx in 90d                   • Low mortality risk
      • Unit MRSA > 20%          or Ampicillin/          • Septic shock / Ventilatory support    • Unit Gram (-) res < 10%
      • High mortality risk      sulbactam               • Unit Gram (-) resistance > 10%        • No prior IV abx
      --> Vancomycin or                                  --> Beta-Lactam + FQ or Aminoglycoside  --> Beta-Lactam Monotherapy
          Linezolid

1. Empiric MRSA Coverage:

   • Indications: Prior parenteral antimicrobial therapy within 90 days; hospital units where $> 20\%$ of S. aureus isolates are methicillin-resistant or local MRSA prevalence is unknown; or high risk of mortality (need for ventilatory support due to HAP, or presence of septic shock).
   • Agents: Vancomycin (15–20 mg/kg IV q8–12h with AUC monitoring) OR Linezolid (600 mg IV q12h).
   • If no MRSA risk factors exist, MSSA coverage is sufficient (cefazolin 2 g IV q8h, oxacillin 2 g IV q4h, or the antipseudomonal beta-lactam).

2. Double Antipseudomonal / Gram-Negative Coverage:

   • Combining two antipseudomonal agents from different pharmacological classes (e.g., antipseudomonal beta-lactam PLUS antipseudomonal fluoroquinolone or aminoglycoside) is indicated in the presence of:
     1. Prior IV antimicrobial use within the preceding 90 days.
     2. Hospitalization in an ICU where $> 10\%$ of Gram-negative bacilli are resistant to an agent being evaluated for monotherapy.
     3. High mortality risk (septic shock or mechanical ventilation requirement due to HAP).
   • Antipseudomonal Beta-Lactams: Piperacillin-tazobactam 4.5 g IV q6h (extended infusion), Cefepime 2 g IV q8h, Ceftazidime 2 g IV q8h, Meropenem 1 g IV q8h, or Imipenem-cilastatin 500 mg IV q6h.
   • Second Antipseudomonal Class: Ciprofloxacin 400 mg IV q8h, Levofloxacin 750 mg IV q24h, Amikacin 15–20 mg/kg IV q24h, Tobramycin 5–7 mg/kg IV q24h, or Gentamicin 5–7 mg/kg IV q24h.

Role of Aerosolized (Inhaled) Antibiotics

Systemic intravenous penetration into the infected, under-ventilated lung parenchyma and alveolar epithelial lining fluid can be suboptimal, particularly for hydrophilic, poorly distributing molecules like polymyxins and aminoglycosides.

• The 2016 IDSA/ATS guidelines recommend adjunctive aerosolized antibiotics (e.g., inhaled colistimethate sodium [CMS] or inhaled tobramycin) ONLY for VAP caused by Gram-negative bacilli that are susceptible only to aminoglycosides or polymyxins (colistin), or in patients not responding to intravenous therapy alone.
• Inhaled administration generates local alveolar concentrations up to 100-fold higher than minimum inhibitory concentrations while maintaining low systemic serum concentrations, mitigating systemic nephrotoxicity.
• Aerosolized antibiotics must NEVER be utilized as monotherapy; they are strictly adjunctive to systemic intravenous antimicrobials.

Duration of Therapy: The 7-Day Rule

The 2016 IDSA/ATS guidelines recommend a 7-day course of antimicrobial therapy for both HAP and VAP (Strong recommendation, moderate-quality evidence), in contrast to historical 14- to 21-day paradigms. This 7-day rule applies equally to non-fermenting Gram-negative pathogens, including Pseudomonas aeruginosa, provided clinical stability and resolution of signs of infection are achieved. Multiple randomized controlled trials demonstrate that 7 days produces identical clinical cure and mortality rates compared to longer durations while significantly reducing antibiotic exposure, adverse drug events, and recurrent colonization with resistant superinfections.

---

Upper Respiratory Tract Infections (URTIs)

Acute Bacterial Rhinosinusitis (ABRS)

Viral rhinosinusitis accounts for 90% to 98% of all rhinosinusitis episodes. Clinical diagnostic criteria are vital to avoid inappropriate antibiotic exposure.

                               Clinical Criteria for Bacterial Rhinosinusitis (ABRS)
                                                       │
              ┌────────────────────────────────────────┼────────────────────────────────────────┐
              ▼                                        ▼                                        ▼
    Persistent Symptoms                     Severe Symptoms Onset                     "Double Sickening"
    Signs/symptoms lasting $\ge 10$ days     High fever ($\ge 39^\circ\text{C}$) AND     Initial typical viral URI
    without any evidence of                 purulent nasal discharge lasting          improves for 3–5 days, followed
    clinical improvement                    $\ge 3–4$ consecutive days                by sudden acute worsening

• Microbiology: Streptococcus pneumoniae, unencapsulated Haemophilus influenzae, and Moraxella catarrhalis.
• First-Line Pharmacotherapy:
  • Standard-Dose Amoxicillin-Clavulanate: 875/125 mg orally twice daily (5–7 days in adults).
  • High-Dose Amoxicillin-Clavulanate (2000/125 mg PO BID): Indicated for patients with risk factors for penicillin-nonsusceptible S. pneumoniae (PRSP): geographic endemic PRSP rates $\ge 10\%$, age $< 2$ or $> 65$ years, prior antibiotic exposure within the past 30 days, recent hospitalization within 5 days, or immunocompromising conditions.
• Penicillin Allergy Alternatives: Doxycycline 100 mg PO BID, Levofloxacin 500 mg PO daily, or Moxifloxacin 400 mg PO daily. Macrolides, trimethoprim-sulfamethoxazole (TMP-SMX), and second/third-generation oral cephalosporin monotherapy are NOT recommended due to elevated resistance rates among S. pneumoniae ($> 30–40\%$) and H. influenzae.

Group A Streptococcal (GAS) Pharyngitis

Streptococcus pyogenes (Group A beta-hemolytic Streptococcus) accounts for 5% to 15% of adult and 20% to 30% of pediatric pharyngitis cases. Clinical decision tools (Centor criteria: fever, tonsillar exudates, tender anterior cervical lymphadenopathy, absence of cough) guide diagnostic testing via Rapid Antigen Detection Testing (RADT) or throat culture.

• Treatment Goals: Primary objectives are symptom reduction, prevention of suppurative complications (peritonsillar abscess), and prevention of non-suppurative sequelae—specifically acute rheumatic fever (ARF). Antibiotic therapy initiated within 9 days of symptom onset reliably prevents ARF. Note: Antimicrobial therapy does not prevent post-streptococcal glomerulonephritis (PSGN).
• First-Line Pharmacotherapy:
  • Penicillin V 500 mg PO twice or three times daily for 10 days, OR
  • Amoxicillin 500 mg PO twice daily (or 1000 mg once daily) for 10 days.
  • Resistance: To date, zero documented clinical isolates of S. pyogenes exhibit intrinsic resistance to penicillin.
• Penicillin Allergy Alternatives:
  • Non-anaphylactic (mild) allergy: First-generation cephalosporin (Cephalexin 500 mg PO BID for 10 days or Cefadroxil 1 g PO daily).
  • Severe / IgE-mediated anaphylaxis: Clindamycin 300 mg PO TID for 10 days, or Azithromycin 500 mg day 1 then 250 mg daily for 4 days (recognizing 10%–15% regional macrolide resistance).

Acute Otitis Media (AOM)

Pediatric AOM is driven by S. pneumoniae, non-typeable H. influenzae, and M. catarrhalis.

• First-Line Pharmacotherapy: High-dose amoxicillin (80–90 mg/kg/day divided twice daily). High dosing saturates altered low-affinity penicillin-binding proteins in penicillin-intermediate and resistant pneumococci, achieving middle ear fluid concentrations above the MIC for $> 40–50\%$ of the dosing interval.
• High-Dose Amoxicillin-Clavulanate (14:1 formulation; 90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate): Indicated if amoxicillin was administered within the prior 30 days, in concurrent purulent conjunctivitis ("otitis-conjunctivitis syndrome," typically H. influenzae), or if initial amoxicillin fails after 48–72 hours. Formulating at a 14:1 ratio preserves high amoxicillin dosing while avoiding excess clavulanate, which causes gastrointestinal hypermotility, secretory diarrhea, and mucosal irritation.

Acute Exacerbations of Chronic Bronchitis / COPD (AECOPD)

Antibiotic therapy in AECOPD is guided by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) / Anthonisen criteria:

• Indications for Antimicrobials:
  1. Presence of all three cardinal symptoms: increased dyspnea, increased sputum volume, and increased sputum purulence.
  2. Presence of two cardinal symptoms, provided that increased sputum purulence is one of the two.
  3. Any patient requiring mechanical ventilatory support (invasive or non-invasive BiPAP).
• Therapeutic Regimens: Target H. influenzae, M. catarrhalis, and S. pneumoniae. Amoxicillin-clavulanate (875/125 mg PO BID), Azithromycin (500 mg day 1, 250 mg daily), or Doxycycline (100 mg PO BID) for 5 days duration. In patients with risk factors for Pseudomonas aeruginosa (severe airflow obstruction [$\text{FEV}_1 < 50\%$], bronchiectasis, or frequent systemic corticosteroid and broad-spectrum antibiotic exposure), oral levofloxacin 750 mg daily or ciprofloxacin 500–750 mg BID is indicated.

---

Aspiration Pneumonia and Lung Abscess

Aspiration Pneumonitis vs. Aspiration Pneumonia

It is clinically imperative to distinguish between chemical aspiration pneumonitis and bacterial aspiration pneumonia:

Anaerobic Coverage Indications

Historical teachings mandated obligate anaerobic coverage for all suspected aspiration events. However, contemporary molecular microbiological analyses demonstrate that early community-acquired aspiration pneumonia is predominantly driven by typical virulent streptococci (Streptococcus anginosus group, S. pneumoniae) and Gram-negative Enterobacterales, whereas obligate oral anaerobes (Bacteroides, Prevotella, Fusobacterium, Peptostreptococcus) act as secondary colonizers.

When anaerobic coverage is indicated:

• First-Line Regimens: Ampicillin-sulbactam (1.5–3 g IV q6h), Amoxicillin-clavulanate (875/125 mg PO BID), or Moxifloxacin (400 mg IV/PO daily).
• Hospital-Acquired / Nosocomial Aspiration: Piperacillin-tazobactam (4.5 g IV q6h) or Meropenem (1 g IV q8h) to cover hospital-acquired Enterobacterales, Pseudomonas aeruginosa, and resistant anaerobes (Bacteroides fragilis).
• Antimicrobial Pitfalls:
  • Clindamycin: Historically favored, but contemporary resistance among Bacteroides fragilis group isolates exceeds 35% to 45%, and clindamycin carries an exceptionally high risk of inducing Clostridioides difficile colitis.
  • Metronidazole Monotherapy: Metronidazole must NEVER be used as monotherapy for lung abscess or aspiration pneumonia. While potent against obligate anaerobes, metronidazole possesses zero antimicrobial activity against microaerophilic streptococci (Streptococcus milleri/anginosus group) and typical aerobic pathogens, resulting in high rates of therapeutic failure unless paired with a beta-lactam.
• Treatment Duration for Lung Abscess: Requires prolonged therapy, typically 3 to 6 weeks (or longer), until follow-up computed tomography or chest radiography demonstrates complete radiographic resolution or a small, stable, fibrotic residual scar.